Products from BPS Bioscience require a minimum order value above 400€
Application: Use as a negative control when testing EGFR inhibitors in A549 cells.Study phenotypes resulting from EGFR knockout.
Background: EGFR (epidermal growth factor receptor), also known as ERBB-1 and HER1, is the cell-surface tyrosine kinase receptor for members of the epidermal growth factor family. Its ligands include EGF, TGFα (transforming growth factor alpha), HB-EGF (heparin-binding EGF), betacellulin, amphiregulin, epiregulin and epigen. EGFR exists as an inactive monomer until it gets activated. Upon ligand binding it forms an asymmetric dimer, for instance with HER2 (human epidermal growth factor receptor 2), which induces autophosphorylation, creating binding sites for adaptor proteins such as GRB2 (growth factor receptor-bound protein 2) and/or CBL (Casitas B-lineage lymphoma). EGFR can bind to several adaptor proteins simultaneously and thus activate multiple positive and negative signaling pathways. Overexpression and/or hyperactivation of EGFR kinase is associated with several human cancers such as lung, glioblastoma (GBM), and epithelial tumors of the neck and head, being the most common mutation in GBM and breast cancer. Mutations in EGFR can result in constantly activated EGFR, allowing tumor cell proliferation and development of resistance to drugs. Its role in cancer has led to the development of anticancer therapeutics targeting EGFR. There are several clinically approved inhibitors, such as Erlotinib and Gefitinib, for the treatment of NSCLC (non-small cell lung cancer) and pancreatic cancer. In addition, several monoclonal antibodies have also been approved, namely Cetuximab. Patients that respond to treatment to anti-EGFR therapy tend to develop resistance later on, highlighting the need for further detailed studies into the role of this protein and new therapeutic avenues.
Description: EGFR Knockout A549 Cell Line is an A549 lung cancer cell line in which human EGFR (epidermal growth factor receptor) has been genetically removed using CRISPR/Cas9 genome editing with a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human EGFR.This cell line has been validated by genomic sequencing and flow cytometry.
Host Cell Line: A549 is a human lung alveolar vessel carcinoma cell line. Adherent epithelial cells.
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Uniprot: P00533
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-1
References: Nakamura J.L., 2007 Expert Opin. Ther. Targets 11(4):463-472.
Uribe MK., et al., 2021 Cancers (Basel) 13(11):2748.
English
Deutsch
